We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. MILAN — A basket study of a new topical ...
Giving patients with chronic obstructive pulmonary disease (COPD) newly available oral phosphodiesterase 4 (PDE4) inhibitors, roflumilast or cilomilast, improves lung function and reduces the ...
The landscape of phosphodiesterase 3/4 (PDE3/4) inhibitors is experiencing a significant transformation in 2025, driven by ...
Janus kinase (JAK) and phosphodiesterase-4 (PDE-4) inhibitors were primary topics covered at the third symposium at the Revolutionizing Atopic Dermatitis fifth annual conference. New insights into the ...
Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — Treatment with an oral preferential phosphodiesterase 4B inhibitor prevented lung function ...
Every major drug therapy for psoriatic arthritis (PsA) -- with one notable exception -- was shown to be effective in treating skin disease in this population, according to a review published in The ...
WASHINGTON -- Treatment with the first-in-class dual phosphodiesterase 3/4 inhibitor ensifentrine reduced exacerbation rates and improved other key outcomes in patients with chronic obstructive ...
Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses the mechanism of action for roflumilast cream, the only phosphodiesterase-4 inhibitor approved by the FDA ...
Once-daily topical roflumilast, a potent selective topical phosphodiesterase-4 inhibitor, brought marked improvement in signs and symptoms of chronic plaque psoriasis — including challenging lesions ...
Detailed price information for Palisade Bio Inc (PALI-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback